Citations

Showing 10 of 108094 citations.

On the Non-invasive Sensing of Arterial Waveform and Hematocrit using Microwaves
Gaddam, Sunil , Samaddar, Poulami , Khan, Muhammad Rehan , Damani, Devanshi N. , Shivaram, Suganti, Mitra, Dipankar , Arunachalam, S P , Roy, Sayan , Dey, Shuvashis , Arunachalam, Shivaram P.

Mayo Clinic

2022 IEEE International Symposium on Antennas and Propagation and USNC-URSI Radio Science Meeting (AP-S/URSI) | September 21, 2022 | Volume: No volume available | Issue: No issue available | Pages: 1070-1071

10.1109/ap-s/usnc-ursi47032.2022.9886974 Get It

On the Effects of the Measured Dielectric Properties at Variable Thickness of Biological Tissue Samples using Open-Ended Coaxial Probe Method
Samaddar, Poulami , Gaddam, Sunil , K, Pratik Sinai, Khan, Muhammad Rehan , Mitra, Dipankar , Leggett, Cadman L. , Arunachalam, S P , Leggett, Cadman L , K., Pratik Sinai, Roy, Sayan , Arunachalam, Shivaram P.

Mayo Clinic

2022 IEEE International Symposium on Antennas and Propagation and USNC-URSI Radio Science Meeting (AP-S/URSI) | September 21, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1109/ap-s/usnc-ursi47032.2022.9886949 Get It

Within-Person Blood Pressure Variability During Hospitalization and Clinical Outcomes Following First-Ever Acute Ischemic Stroke
Yousufuddin, Mohammed , Peters, Jessica , Ambriz, Taylor J, Blocker, Katherine R., Khandelwal, Kanika , Pagali, Sandeep R. , Nanda, S. , Abdalrhim, Ahmed D., Dugani, Sagar B. , Arumaithurai, Kogulavadanan , Peters, Jessica L, Abdalrhim, Ahmed, DUGANI, SAGAR, Takahashi, Paul Y. , Pagali, Sandeep , Dugani, Sagar B , Murad, M. Hassan , Peters, Jessica L, Patel, Urvish , Kashani, Kianoush

Mayo Clinic

American Journal of Hypertension | September 21, 2022 | Volume: 36 | Issue: 1 | Pages: 23-32

10.1093/ajh/hpac106 | PMID 36130108 Get It

Abstract BACKGROUND Uncertainty remains over the relationship between blood pressure (BP) variability (BPV), measured in hospital settings, and clinical outcomes following acute ischemic stroke (AIS). We examined the association between within-person systolic blood pressure (SBP) variability (SBPV) during hospitalization and readmission-free survival, all-cause readmission, or all-cause mortality 1 year after AIS. METHODS In a cohort of 862 consecutive patients (age [mean ± SD] 75 ± 15 years, 55% women) with AIS (2005–2018, follow-up through 2019), we measured SBPV as quartiles of standard deviations (SD) and coefficient of variation (CV) from a median of 16 SBP readings obtained throughout hospitalization. RESULTS In the cumulative cohort, the measured SD and CV of SBP in mmHg were 16 ± 6 and 10 ± 5, respectively. The hazard ratios (HR) for readmission-free survival between the highest vs. lowest quartiles were 1.44 (95% confidence interval [CI] 1.04–1.81) for SD and 1.29 (95% CI 0.94–1.78) for CV after adjustment for demographics and comorbidities. Similarly, incident readmission or mortality remained consistent between the highest vs. lowest quartiles of SD and CV (readmission: HR 1.29 [95% CI 0.90–1.78] for SD, HR 1.29 [95% CI 0.94–1.78] for CV; mortality: HR 1.15 [95% CI 0.71–1.87] for SD, HR 0.86 [95% CI 0.55–1.36] for CV). CONCULSIONS In patients with first AIS, SBPV measured as quartiles of SD or CV based on multiple readings throughout hospitalization has no independent prognostic implications for the readmission-free survival, readmission, or mortality. This underscores the importance of overall patient care rather than a specific focus on BP parameters during hospitalization for AIS.
Patient perspectives on testing for clonal hematopoiesis of indeterminate potential
Sella, Tal , Fell, Geoffrey, Miller, Peter G. , Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Peppercorn, Jeffrey , Schapira, Lidia , Come, Steven E. , Ebert, Benjamin L. , Stover, Daniel G , Ruddy, Kathryn J , Ebert, Benjamin L , Fell, Geoffrey G. , Gibson, Christopher James , Snow, Craig , Stover, Daniel G. , Borges, Virginia F. , Warner, Ellen , Frank, Elizabeth S. , Neuberg, Donna , Partridge, Ann H.

Mayo Clinic

Blood Advances | September 21, 2022 | Volume: 6 | Issue: 24 | Pages: 6151-6161

10.1182/bloodadvances.2022008376 | PMID 36129839 Get It

Abstract Clonal hematopoiesis of indeterminate potential (CHIP), an emerging biomarker for personalized risk-directed interventions, is increased in cancer survivors. However, little is known about patient preferences for CHIP testing. We surveyed participants in a prospective cohort study of young women with breast cancer (BC). The emailed survey included an introduction to CHIP and a vignette eliciting participants’ preferences for CHIP testing, considering sequentially: population-based 10-year risk of BC recurrence, hematologic malignancy, and heart disease; increased CHIP-associated risks; current CHIP management; dedicated CHIP clinic; and hypothetical CHIP treatment. Preference changes were evaluated using the McNemar test. The survey response rate was 82.2% (528/642). Median age at time of survey was 46 years and median time from diagnosis was 108 months. Only 5.9% had prior knowledge of CHIP. After vignette presentation, most survivors (87.1%) recommended CHIP testing for the vignette patient. Presented next with CHIP-independent, population-based risks, 11.1% shifted their preference from testing to not testing. After receiving information about CHIP-associated risks, an additional 10.1% shifted their preference to testing. Preference for testing increased if vignette patient was offered a CHIP clinic or hypothetical CHIP treatment, with 7.2% and 14.1% switching preferences toward testing, respectively. Finally, 75.8% of participants desired CHIP testing for themselves. Among participants, 28.2% reported that learning about CHIP caused at least moderate anxiety. Most young survivors favored CHIP testing, with preferences influenced by risk presentation and potential management strategies. Our findings highlight the importance of risk communication and psychosocial support when considering biomarkers for future risk in cancer survivors. This trial has been registered at www.clinicaltrials.gov as #NCT01468246.
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
Duncavage, Eric J., Bagg, Adam , Hasserjian, Robert P. , DiNardo, Courtney D. , Iacobucci, Ilaria , Jaiswal, Siddhartha , Vannucchi, Alessandro M. , Patel, Keyur P. , Arcila, Maria E. , Borowitz, Michael J., Cargo, Catherine , Garcia‐Manero, Guillermo , Haferlach, Torsten , Hellström‐Lindberg, Eva , Klco, Jeffery M. , Loh, Mignon Lee-Cheun, Papaemmanuil, Elli , Reiter, Andreas , Skoda, Radek C. , Solé, Françesc , Stone, Richard M. , Tefferi, Ayalew , Wu, David , Ebert, Benjamin L. , Cazzola, Mario , Godley, Lucy A , Iacobucci, Ilaria , Jaiswal, Siddhartha , Malcovati, Luca , Vannucchi, Alessandro M , Patel, Keyur P , Arber, Daniel A , Bejar, Rafael , Branford, Susan , Brown, Anna L , Döhner, Hartmut , Falini, Brunangelo , Kim, Annette S , Komrokji, Rami S , Loghavi, Sanam , Mullighan, Charles G , Ogawa, Seishi , Ross, David M , Savona, Michael R , Shimamura, Akiko , Solé, Francesc , Walter, Matthew J , Wu, David , Ebert, Benjamin L , Cazzola, Mario , DiNardo, Courtney , Godley, Lucy A. , Malcovati, Luca , Arber, Daniel A. , Berliner, Nancy , Branford, Susan , Brown, Anna , Falini, Brunangelo , Komrokji, Rami S. , Loh, Mignon L. , Loghavi, Sanam , Mullighan, Charles G. , Orazi, Attilio , Savona, Michael R.

Mayo Clinic

Blood | September 21, 2022 | Volume: 140 | Issue: 21 | Pages: 2228-2247

10.1182/blood.2022015853 | PMID 36130297 Get It

Abstract Myeloid neoplasms and acute leukemias derive from the clonal expansion of hematopoietic cells driven by somatic gene mutations. Although assessment of morphology plays a crucial role in the diagnostic evaluation of patients with these malignancies, genomic characterization has become increasingly important for accurate diagnosis, risk assessment, and therapeutic decision making. Conventional cytogenetics, a comprehensive and unbiased method for assessing chromosomal abnormalities, has been the mainstay of genomic testing over the past several decades and remains relevant today. However, more recent advances in sequencing technology have increased our ability to detect somatic mutations through the use of targeted gene panels, whole-exome sequencing, whole-genome sequencing, and whole-transcriptome sequencing or RNA sequencing. In patients with myeloid neoplasms, whole-genome sequencing represents a potential replacement for both conventional cytogenetic and sequencing approaches, providing rapid and accurate comprehensive genomic profiling. DNA sequencing methods are used not only for detecting somatically acquired gene mutations but also for identifying germline gene mutations associated with inherited predisposition to hematologic neoplasms. The 2022 International Consensus Classification of myeloid neoplasms and acute leukemias makes extensive use of genomic data. The aim of this report is to help physicians and laboratorians implement genomic testing for diagnosis, risk stratification, and clinical decision making and illustrates the potential of genomic profiling for enabling personalized medicine in patients with hematologic neoplasms.
Towards Non-Invasive Mapping of Blood Flow Velocity using Microwaves
Gaddam, Sunil , Samaddar, Poulami , Khan, Muhammad Rehan , Damani, Devanshi N. , Shivaram, Suganti, Mitra, Dipankar , Arunachalam, S P , Roy, Sayan , Dey, Shuvashis , Arunachalam, Shivaram P.

Mayo Clinic

2022 IEEE International Symposium on Antennas and Propagation and USNC-URSI Radio Science Meeting (AP-S/URSI) | September 21, 2022 | Volume: No volume available | Issue: No issue available | Pages: 1326-1327

10.1109/ap-s/usnc-ursi47032.2022.9886579 Get It

Gastric dysfunction in patients with chronic nausea and vomiting syndromes defined by a noninvasive gastric mapping device
Gharibans, Armen A. , Calder, Stefan , Varghese, Chris , Waite, Stephen , Schamberg, Gabriel , Daker, Charlotte , Du, Peng , Carson, D A, Woodhead, Jonathan S. T., Farrugia, Gianrico , Windsor, John A. , Andrews, Christopher N. , O’Grady, Greg, Alighaleh, Saeed , Carson, Daniel , Farrugia, Gianrico , O'Grady, Gregory , Varghese, Chris , Gharibans, Armen A , Andrews, Christopher N , Schamberg, Gabriel , Daker, Charlotte

Mayo Clinic

Science Translational Medicine | September 21, 2022 | Volume: 14 | Issue: 663 | Pages: No page available

10.1126/scitranslmed.abq3544 | PMID 36130019 Get It

Chronic nausea and vomiting syndromes (NVSs) are prevalent and debilitating disorders. Putative mechanisms include gastric neuromuscular disease and dysregulation of brain-gut interaction, but clinical tests for objectively defining gastric motor function are lacking. A medical device enabling noninvasive body surface gastric mapping (BSGM) was developed and applied to evaluate NVS pathophysiology. BSGM was performed in 43 patients with NVS and 43 matched controls using Gastric Alimetry (Alimetry), a conformable high-resolution array (8 × 8 electrodes; 20-mm interelectrode spacing), wearable reader, and validated symptom-logging app. Continuous measurement encompassed a fasting baseline (30 minutes), 482-kilocalorie meal, and 4-hour postprandial recording, followed by spectral and spatial biomarker analyses. Meal responses were impaired in NVS, with reduced amplitudes compared to controls (median, 23.3 microvolts versus 38.0 microvolts, P < 0.001), impaired fed-fasting power ratios (1.1 versus 1.6, P = 0.02), and disorganized slow waves (spatial frequency stability, 13.6 versus 49.5; P < 0.001). Two distinct NVS subgroups were evident with indistinguishable symptoms (all P > 0.05). Most patients (62%) had normal BSGM studies with increased psychological comorbidities (43.5% versus 7.7%; P = 0.03) and anxiety scores (median, 16.5 versus 13.0; P = 0.035). A smaller subgroup (31%) had markedly abnormal BSGM, with biomarkers correlating with symptoms (nausea, pain, excessive fullness, early satiety, and bloating; all r > 0.35, P < 0.05). Patients with NVS share overlapping symptoms but comprise distinct underlying phenotypes as revealed by a BSGM device. These phenotypes correlate with symptoms, which should inform clinical management and therapeutic trial design.
Low postoperative lymphocyte count increases risk of progression in human papillomavirus associated oropharyngeal cancer
Routman, David M. , Day, Courtney N. , Harmsen, William S. , Haller, Travis J. , Moore, Eric J. , Foote, Robert L. , Neben-Wittich, M.A. , Price, Katharine A. , Abel, Kathryn M. Van , Haller, Travis, Moore, Eric J , Neben-Wittich, Michelle, Van Abel, Kathryn M , Routman, David M , Yin, Linda X. , Bartemes, Kathleen R. , Price, Daniel L. , Chintakuntlawar, Ashish V. , Daniel, J.

Mayo Clinic

Head & Neck | September 21, 2022 | Volume: 44 | Issue: 12 | Pages: 2760-2768

10.1002/hed.27198 | PMID 36129387 Get It

AbstractBackgroundWe aim to explore the prognostic role of absolute lymphocyte count (ALC) before, during, and after treatment on oncologic outcomes in human papillomavirus associated oropharyngeal cancer (HPV(+)OPSCC).MethodsRetrospective cohort at a tertiary center, 2006–2018. Multivariable Cox regressions were used to determine the effect of ALC on risk of progression. Univariate linear regression was performed to determine clinical factors associated with lower ALC.ResultsAll 197 patients underwent primary surgery. Mean (SD) ALC nadirs (×109 cells/L) were: baseline (N = 149): 1.69 (0.56); postoperative (N = 126): 1.58 (0.59); post‐RT (N = 141): 0.68 (0.35) and long‐term (N = 105): 0.88 (0.37). Lower baseline ALC nadir was associated with worse overall survival (HR 3.85, 95%CI: 1.03–14.29, p = 0.04). Lower postoperative ALC nadir was associated with higher risk of progression (HR 2.63, 95%CI: 1.04–6.67, p = 0.04).ConclusionsLower baseline ALC is associated with worse survival, whereas lower postoperative ALC is associated with increased risk of progression in surgically treated HPV(+)OPSCC.Level of Evidence3
CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer
Wei, Ting , Ding, Donglin , Zhang, Jianong , He, Housheng Hansen , Wang, Liguo , Sun, Rui , Wei, Ting , He, Housheng Hansen , Wang, Liguo , Sun, Rui , Chen, Sujun , Huang, Haojie , Sun, Rui

Mayo Clinic

Proceedings of the National Academy of Sciences | September 21, 2022 | Volume: 119 | Issue: 39 | Pages: No page available

10.1073/pnas.2205509119 | PMID 36129942 Get It

Androgen receptor (AR) messenger RNA (mRNA) alternative splicing variants (AR-Vs) are implicated in castration-resistant progression of prostate cancer (PCa), although the molecular mechanism underlying the genesis of AR-Vs remains poorly understood. The CDK12 gene is often deleted or mutated in PCa and CDK12 deficiency is known to cause homologous recombination repair gene alteration or BRCAness via alternative polyadenylation (APA). Here, we demonstrate that pharmacological inhibition or genetic inactivation of CDK12 induces AR gene intronic (intron 3) polyadenylation (IPA) usage, AR-V expression, and PCa cell resistance to the antiandrogen enzalutamide (ENZ). We further show that AR binds to the CCNK gene promoter and up-regulates CYCLIN K expression. In contrast, ENZ decreases AR occupancy at the CCNK gene promoter and suppresses CYCLIN K expression. Similar to the effect of the CDK12 inhibitor, CYCLIN K degrader or ENZ treatment promotes AR gene IPA usage, AR-V expression, and ENZ-resistant growth of PCa cells. Importantly, we show that targeting BRCAness induced by CYCLIN K down-regulation with the PARP inhibitor overcomes ENZ resistance. Our findings identify CYCLIN K down-regulation as a key driver of IPA usage, hormonal therapy–induced AR-V expression, and castration resistance in PCa. These results suggest that hormonal therapy–induced AR-V expression and therapy resistance are vulnerable to PARP inhibitor treatment.
Detectability of Small Low-Attenuation Lesions With Deep Learning CT Image Reconstruction: A 24-Reader Phantom Study
Toia, Giuseppe V. , Zamora, D , Singleton, Michael, Shuman, William P. , Kanal, Kalpana M. , Mileto, Achille , Singleton, Michael, Liu, Arthur , Tan, Edward, Leng, Shuai

Mayo Clinic

American Journal of Roentgenology | September 21, 2022 | Volume: 220 | Issue: 2 | Pages: 283-295

10.2214/ajr.22.28407 | PMID 36129222 Get It